We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > NMDA

News List

FDA approves Janssen’s ketamine-based nasal antidepressant pharmaphorum
March 07, 2019
The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted to specialist clinics.
Allergan acquires NMDA depression drug from Aptinyx collaboration fiercebiotech
May 29, 2018
Allergan has acquired an investigational NMDA receptor modulator discovered by Aptinyx, exercising its option under an ongoing collaboration, and plans to pair it with its rapastinel depression therapy currently under development.
Aptinyx seeks $80M IPO to push NMDA drug platform fiercebiotech
May 29, 2018
With the ink barely dry on a partnership deal with Allergan, Aptinyx has announced plans for an $80 million IPO to accelerate work on its drugs for neurological disorders.